Viewing Study NCT01798095


Ignite Creation Date: 2025-12-24 @ 1:33 PM
Ignite Modification Date: 2025-12-31 @ 8:57 AM
Study NCT ID: NCT01798095
Status: UNKNOWN
Last Update Posted: 2013-02-25
First Post: 2013-01-31
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Equivalence Study of Specificity of PPD
Sponsor: JHP Pharmaceuticals LLC
Organization:

Study Overview

Official Title: A Randomized, Double-blind, Equivalence Study of the Specificity of Tuberculin Purified Protein Derivative (PPD) (AplisolĀ®) in Comparison With a Reference Standard
Status: UNKNOWN
Status Verified Date: 2013-02
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: 03
Brief Summary: Determine if investigational products and reference standard produce similar responses.
Detailed Description: Primary:

To determine if the 2 investigational products (Aplisol formulated from the new Tuberculin PPD drug substance and the reference standard PPD-S2) produce qualitatively similar responses (positive or negative) in subjects who are uninfected with M. tuberculosis (Mtb) or other mycobacteria.

Secondary:

1. To determine if the 2 investigational products have equivalent specificity for detecting subjects currently or previously infected with Mtb;
2. To assess the tolerability of the investigational products in terms of the local and systemic reactogenicity events.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: